Archive - March 2022
U.S. Food and Drug Administration Approves Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer
Most Of The US Population Relieved From Mask Duty: Is The Pandemic Over? Experts Weigh In
Almost A Third Of People Report Lingering Symptom 6-12 Months After COVID-19: Study
Almost A Third Of People Report Lingering Symptom 6-12 Months After COVID-19: Study
Is Omicron More Deadly For The Vaccinated?
COVID-19 Infection: What’s The Most Alarming Symptom?
Outbreaks of norovirus increasing in England
Results from trial show Eli Lilly’s COVID-19 drug improves survival rates